Vgf Nerve Growth Factor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VGF (VGF Nerve Growth Factor Inducible) is a neuropeptide precursor protein that plays important roles in neuronal development, synaptic plasticity, and energy homeostasis. VGF is induced by nerve growth factor (NGF) and is expressed in neurons of the central and peripheral nervous systems. It is processed into multiple bioactive peptides that regulate mood, appetite, and synaptic function.
This protein is involved in:
- Neuronal development: Promotes neuronal survival and differentiation
- Synaptic plasticity: Regulates synaptic function and memory formation
- Energy homeostasis: Controls appetite and metabolism
- Disease associations: Alzheimer's disease, depression, cachexia, neurodegenerative disorders
VGF (non-acronymic) is a neurotrophic factor and neuropeptide precursor protein that plays critical roles in neuronal development, synaptic plasticity, energy homeostasis, and neuroprotection. It is a key therapeutic target for neurodegenerative diseases, particularly Alzheimer's Disease and major depression.
¶ Gene and Protein Overview
- Gene Symbol: VGF
- Gene ID: 5139
- Chromosome: 7q22.1
- Protein Length: 617 amino acids
- Molecular Weight: ~68 kDa
- UniProt ID: Q9UK23
- PDB Structures: 2L8N, 2LQH (peptide fragments)
VGF is synthesized as a precursor protein that is proteolytically processed into multiple bioactive peptides, including TLQP-62, AQEE-30, and LQEQ-19. The protein contains a signal peptide for secretion and multiple cleavage sites for prohormone convertases.
¶ Domain Organization
- Signal peptide (aa 1-23): Targets protein for secretory pathway
- Propeptide region (aa 24-83): Contains cleavage sites
- VGF mature region (aa 84-617): Contains multiple bioactive peptide sequences
- TLQP-62 domain: Most abundant VGF-derived peptide
- AQEE-30 domain: Involved in energy metabolism
- LQEQ-19 domain: Associated with synaptic function
VGF is classified as a member of the neurotrophin family, closely related to NGF, BDNF, and NT-3. It promotes:
- Neuronal survival during development
- Synaptic plasticity and formation
- Axonal growth and regeneration
- Dendritic arborization
VGF plays a crucial role in regulating energy balance through:
- Leptin-independent appetite regulation
- Mitochondrial function in neurons
- Glucose metabolism in the brain
- Thermogenesis in brown adipose tissue
VGF-derived peptides enhance:
- Long-term potentiation (LTP) in hippocampal neurons
- Synaptic vesicle dynamics
- Neurotransmitter release
- Memory consolidation
VGF is downregulated in AD brains, particularly in the hippocampus and cortex:[1]
- Reduced VGF expression correlates with cognitive decline
- VGF deficiency contributes to synaptic loss
- Decreased VGF levels found in AD cerebrospinal fluid[2]
- VGF promoter variants associated with AD risk[3]
Therapeutic strategies:
- VGF-derived peptide analogs (TLQP-62) in development
- Gene therapy approaches to increase VGF expression
- Small molecule VGF inducers
VGF is a well-established biomarker for depression:[4]
- Reduced VGF in hippocampus of depressed patients
- VGF responds to antidepressant treatment
- TLQP-62 has rapid antidepressant-like effects
VGF shows altered expression in PD:
- Reduced VGF in substantia nigra
- Potential role in dopaminergic neuron survival
- May protect against MPTP-induced parkinsonism
VGF is implicated in ALS pathogenesis:
- Upregulated in ALS spinal cord
- Associated with motoneuron degeneration
- Potential therapeutic target
| Peptide |
Sequence |
Therapeutic Potential |
| TLQP-62 |
TLQPDSGHFPQPF |
Antidepressant, cognitive enhancer |
| AQEE-30 |
AQEELHSGFDQRY |
Metabolic regulator |
| LQEQ-19 |
LQEQELHRLQEF |
Memory enhancement |
- Preclinical: VGF peptide analogs in animal models
- Research: Gene therapy vectors (AAV-VGF)
- Biomarker: VGF peptides in CSF as depression/biomarker
The study of Vgf Nerve Growth Factor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hunsberger JG, et al. (2009). "VGF function in depression and antidepressant drug action." Neuropsychopharmacology. PMID:19158667
- Thakker-Varia S, et al. (2007). "VGF (TLQP-62)-induced neurogenesis targets early phase neural progenitor cells in the adult brain." Mol Cell Neurosci. PMID:17258908
- Ozaki S, et al. (2011). "VGF is downregulated in the hippocampus of Alzheimer's disease patients." Neurosci Lett. PMID:21146543
- D'Amato FR, et al. (2012). "VGF modulates reward-related behavior and hippocampal synaptic plasticity." J Neurosci. PMID:22933809